April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Selective Laser Trabeculoplasty as Primary and Secondary Therapy in Patients With Glaucoma: 8 Year Experience
Author Affiliations & Notes
  • L. F. Jindra
    Ophthalmology, Columbia University, New York, New York
    Ophthalmology, Winthrop University Hospital, Mineola, New York
  • J. A. Donnelly
    Albert Einstein College of Medicine, Yeshiva University, Bronx, New York
  • A. Gupta
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • E. M. Miglino
    Floral Park Ophthalmology, Floral Park, New York
  • Footnotes
    Commercial Relationships  L.F. Jindra, Lumenis, C; Ellex, R; J.A. Donnelly, None; A. Gupta, None; E.M. Miglino, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4428. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. F. Jindra, J. A. Donnelly, A. Gupta, E. M. Miglino; Selective Laser Trabeculoplasty as Primary and Secondary Therapy in Patients With Glaucoma: 8 Year Experience. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4428.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate Selective Laser Trabeculoplasty (SLT) as primary and secondary therapy, to decrease intraocular pressure (IOP) and glaucoma medication (meds) usage.

Methods: : Retrospective chart review was performed on 1363 and 945, respectively, of 3013 eyes treated with SLT over 8 years. Two-tailed paired t-test was used to compare maximum pre- and post-procedure IOP and number of meds.

Results: : Mean follow-up was 750 and 515 days, respectively. For primary therapy, IOP decreased 31% from mean of 18.8mm Hg to 13.0mm Hg. For IOP control, 87 eyes (6%) required one repeat SLT (15 eyes required multi repeat). After one SLT, 16 eyes (1%) were on meds to control IOP. For SLT as primary (initial) treatment of glaucoma, cumulative probability of success over 7 years was 92%. For secondary therapy, IOP decreased by 22% from mean of 19.8mm Hg to 15.4mm Hg; meds decreased by 60% from a mean of 2.3 to 0.9 meds. For IOP control, reduction in meds' side effects, improvement in compliance, and / or decrease in need for meds, 367 eyes (38%) required one repeat SLT (59 eyes required multi repeat). After one SLT, 540 eyes (57%) were on no meds; 171 eyes (18%) were on less meds (but not zero); 207 eyes (22%) were on the same number of meds; and 27 eyes (3%) were on more meds to control IOP. For SLT as secondary (adjunct) treatment of glaucoma, cumulative probability of success over 7 years was 64%. Results were significant with p<0.01.

Conclusions: : In this large long-term series, SLT significantly lowered IOP and decreased number of meds as, primary and secondary therapy, in patients with glaucoma.

Keywords: laser • intraocular pressure • trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×